Newron Pharmaceuticals SpA (XTER:NP5) EV-to-FCF : -22.73 (As of May. 16, 2024)

Newron Pharmaceuticals SpA EV-to-FCF Chart

Newron Pharmaceuticals SpA Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-FCF		Get a 7-Day Free Trial					-3.70	-1.96	-3.16	-4.58	-12.76

Newron Pharmaceuticals SpA Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-FCF	Get a 7-Day Free Trial															-3.16	-	-4.58	-	-12.76

Competitive Comparison of Newron Pharmaceuticals SpA's EV-to-FCF

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Newron Pharmaceuticals SpA's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's EV-to-FCF falls into.

Newron Pharmaceuticals SpA EV-to-FCF Calculation

Newron Pharmaceuticals SpA's EV-to-FCF for today is calculated as:

Newron Pharmaceuticals SpA's current Enterprise Value is €230.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-10.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA  (XTER:NP5) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Newron Pharmaceuticals SpA's PE Ratio for today is calculated as:

Newron Pharmaceuticals SpA's share price for today is €10.54.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.910.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Newron Pharmaceuticals SpA EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Newron Pharmaceuticals SpA's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Newron Pharmaceuticals SpA (XTER:NP5) Business Description